With more than 30 years of experience in the pharmaceutical industry, Dr Reynolds is founder and principal at JAReynolds & Associates.
Prior to his current role, Dr Reynolds worked at Pfizer Global R&D for nearly 20 years, where he served as senior vice president of R&D and was head of worldwide safety sciences and comparative medicine.
Lansing Taylor, CEO of Cellumen, said: “We are incredibly pleased to welcome Jack to our team. He is highly regarded for his work in early safety testing, and we are confident that he will serve as a trusted advisor for the team at Cellumen, helping us to continue identifying safety liabilities earlier in the drug development process.”